Opinion of the Transparency Council – metoprololum
At its meeting on 14 October 2024, the Transparency Council adopted opinion No. 165/2024on the inclusion in the reimbursement of medicines containing the active substance metoprololum in terms of indications for use or dosage or route of administration different from those specified in the Summary of Product Characteristics